Systemic therapies for intrahepatic cholangiocarcinoma

Robin Kate Kelley(UCSF Helen Diller Family Comprehensive Cancer Center), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai)

Journal of Hepatology

January 15, 2020

10.1016/j.jhep.2019.10.009

Cited by 435

Related Papers

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

|Nature Medicine|2004|2k

Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

|JNCI Journal of the National Cancer Institute|2008|1.7k

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

|NEJM Evidence|2022|1.4k

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2023|1k

Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma

|Liver International|2019|591